Safety and efficacy of CPX-351 in younger patients (< 60 years) with secondary acute myeloid leukemia. Przespolewski A, Goldberg AD, Talati C, Fazal S, et al. Blood 2022 Dec 9:blood.2022016678. doi: 10.1182/blood.2022016678.

Read + Share

Amedeo Smart

Independent Medical Education

Przespolewski A, Goldberg AD, Talati C, Fazal S, et al. Safety and efficacy of CPX-351 in younger patients (< 60 years) with secondary acute myeloid leukemia. Blood 2022 Dec 9:blood.2022016678. doi: 10.1182/blood.2022016678.
PMID: 36493344